Prognostic importance of SUVmax values evaluated by 18F-FDG-PET/CT before nivolumab treatment in patients with metastatic renal cell carcinoma

Gültürk, İlkay; Yılmaz, Mesut; Tacar, Seher Yıldız; Tural, Deniz

doi:10.23736/s1824-4785.21.03395-1

Cited by 2 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1. An overview of several malignancies commonly treated with ICIs (alone or in combination therapy) [15,17,19,[22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39]. NSCLC-non-small cell lung cancer, SCLC-small cell lung cancer, MSI-H or dMMR CRC-Microsatellite-high or deficient mismatch repair colorectal carcinoma, BCC-Basal cell carcinoma, CSCC-cutaneous squamous cell carcinoma, ESCC-esophageal squamous cell carcinoma.…”

Section: Malignancies Commonly Treated With Icismentioning

confidence: 99%

Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons

Karlsen,

Akily,

Mierzejewska

et al. 2024

Cancers

View full text Add to dashboard Cite

Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized contemporary oncology, presenting efficacy in various solid tumors and lymphomas. However, ICIs may potentially overstimulate the immune system, leading to immune-related adverse events (irAEs). IrAEs may affect multiple organs, such as the colon, stomach, small intestine, kidneys, skin, lungs, joints, liver, lymph nodes, bone marrow, brain, heart, and endocrine glands (e.g., pancreas, thyroid, or adrenal glands), exhibiting autoimmune inflammation. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is commonly used in oncology for staging and assessment of therapy responses, but it may also serve as a tool for detecting irAEs. This review aims to present various patterns of metabolic activation associated with irAEs due to ICI treatment, identifiable through 18F-FDG PET/CT. It describes the advantages of early detection of irAEs, but also presents the challenges in differentiating them from tumor progression. It also delves into aspects of molecular response assessment within the context of pseudoprogression and hyperprogression, along with typical imaging findings related to these phenomena. Lastly, it summarizes the role of functional PET imaging in oncological immunotherapy, speculating on its future significance and limitations.

show abstract

Section: Malignancies Commonly Treated With Icismentioning

confidence: 99%

Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons

Karlsen,

Akily,

Mierzejewska

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy

Gao

Chen

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Cancer immunotherapy, especially immune-checkpoint inhibitors (ICIs), has paved a new way for the treatment of many types of malignancies, particularly advanced-stage cancers. Accumulating evidence suggests that as a molecular imaging modality, positron emission tomography/computed tomography (PET/CT) can play a vital role in the management of ICIs therapy by using different molecular probes and metabolic parameters. In this review, we will provide a comprehensive overview of the clinical data to support the importance of 18F-fluorodeoxyglucose PET/CT (18F-FDG PET/CT) imaging in the treatment of ICIs, including the evaluation of the tumor microenvironment, discovery of immune-related adverse events, evaluation of therapeutic efficacy, and prediction of therapeutic prognosis. We also discuss perspectives on the development direction of 18F-FDG PET/CT imaging, with a particular emphasis on possible challenges in the future. In addition, we summarize the researches on novel PET molecular probes that are expected to potentially promote the precise application of ICIs.

show abstract

Prognostic importance of SUVmax values evaluated by 18F-FDG-PET/CT before nivolumab treatment in patients with metastatic renal cell carcinoma

Cited by 2 publications

References 34 publications

Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons

Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons

PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy

Contact Info

Product

Resources

About